CD274 and cancer: This hypothesis was supported by a meta-analysis of studies examining the association between PD-L1 expression and mortality in RCC patients before the widespread adoption of ICI, the adjusted hazard ratio for cancer-specific death was 1.81 (95% CI 1.31–2.49) for patients with tumoural PD-L1 expression compared with those without [10].